TD Cowen Remains a Buy on AstraZeneca (AZN)
TD Cowen analyst Steve Scala maintained a Buy rating on AstraZeneca today and set a price target of $105.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Scala covers the Healthcare sector, focusing on stocks such as Pfizer, Eli Lilly & Co, and Novartis. According to TipRanks, Scala has an average return of 10.6% and a 63.64% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for AstraZeneca with a $99.67 average price target.
Based on AstraZeneca’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $15.19 billion and a net profit of $2.53 billion. In comparison, last year the company earned a revenue of $13.57 billion and had a net profit of $1.43 billion
Read More on AZN:
Disclaimer & DisclosureReport an Issue
- AstraZeneca price target raised to 16,000 GBp from 14,000 GBp at JPMorgan
- JPMorgan ups AstraZeneca target, adds to Analyst Focus List
- Trump Weekly: President approves U.S. manufacturing of ‘tiny cars’
- Salesforce (CRM) Wins AstraZeneca Deal, Becomes the Unified Global Platform
- Salesforce’s Agentforce selected by AstraZeneca as unified global platform
